The credit facility, available through Sept. 17, 2024, replaces a prior credit facility dated Aug. 11, 2016 for $1 billion.
The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.
About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.
The IVD industry is optimistic that political tensions between the US and China won't slow down their businesses. However, other challenges may lay ahead for them.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
Get the latest news from Biocept, Caris Life Sciences, PerkinElmer, Inform Diagnostics, CompuNet Clinical Labs, and Drawbridge Health for the week of 7/26/19.
The first tests to be made available through the collaboration will be for Lyme disease and food sensitivity, leveraging PerkinElmer's expertise.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders.